Latest Abarceo Pharma News & Updates

See the latest news and media coverage for Abarceo. We track all announcements, press releases, and industry mentions in real time, all in one place.

Abarceo Pharma (Abarceo)

Preclinical biotechnology company developing mitochondrial disease therapeutics

Last updated Today

Latest news about Abarceo Pharma (Abarceo)

In short: Abarceo presented its oral diabetes treatments and mitochondrial repair platforms at various industry events and investor summits.

September 11 Abarceo

CEO Adam Bruce will attend the September 22 investor event to showcase oral treatments for Type1 Diabetes and mitochondrial dysfunction platforms.

March 29 Abarceo

From 11–14 March in Barcelona, Abarceo promotes its diabetes drug restoring insulin secretion, improving sensitivity via daily oral pill.

23 May 2025 Abarceo

Groundbreaking data on VDAC1 inhibitors is revealed at the 5th Swedish Diabetes Summit via poster by Ruchi Jain and Claes Wollheim.

1 March 2021 Abarceo

The company raises a total of 21.5 million kronor to develop drug candidates against type 2 diabetes.

Never miss news about Abarceo

Track Abarceo and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Browse news for competitors to Abarceo and other trending companies.